Clinical Study

Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study

Vijayshree Yadav,1 Dennis N. Bourdette,1, 2 James D. Bowen,3 Sharon G. Lynch,4 David Mattson,5 Jana Preiningerova,6 Christopher T. Bever Jr.,7 Jack Simon,2 Andrew Goldstein,8 Gregory G. Burrows,1 Halina Offner,1, 2, 9 Al J. Ferro,8 and Arthur A. Vandenbark1, 2, 10, 11

1Department of Neurology, Oregon Health & Science University, L226, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
2Department of Veterans Affairs Medical Center, Portland, OR 97239, USA
3Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA 98122, USA
4Department of Neurology, University of Kansas Medical Center, Kansas City, KS 66160, USA
5Department of Neurology, Indiana University School of Medicine, Indiana University MS Center, Indianapolis, IN 46202, USA
6Multiple Sclerosis Center, Yale University, New Haven, CT 06510, USA
7Department of Neurology, School of Medicine University of Maryland, Baltimore, MD 21201, USA
8Artielle ImmunoTherapeutics Inc., Tigard, OR 97223, USA
9Department of Anesthesiology & Perioperative Medicine, Oregon Health & Science University, Portland, OR 97239, USA
10Senior Research Career Scientist, Research Service, Medical Center Department of Veterans Affairs Portland VA, Portland, OR 97239, USA
11Department of Molecular Microbiology & Immunology, Oregon Health & Science University, Portland, OR 97239, USA

Correspondence should be addressed to Vijayshree Yadav, yadavv@ohsu.edu

Received 6 October 2011; Revised 15 January 2012; Accepted 16 January 2012

Academic Editor: Kamal D. Moudgil

Copyright © 2012 Vijayshree Yadav et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Recombinant T-cell receptor ligand 1000 (RTL1000) is a single-chain protein construct containing the outer two domains of HLA-DR2 linked to myelin-oligodendrocyte-glycoprotein- (MOG-) 35–55 peptide. Analogues of RTL1000 induce T-cell tolerance, reverse clinical and histological disease, and promote repair in experimental autoimmune encephalomyelitis (EAE) in DR2 transgenic, C57BL/6, and SJL/J mice. Objective. Determining the maximum tolerated dose, safety, and tolerability of RTL1000 in multiple sclerosis (MS) subjects. Methods. This was a multicenter, Phase I dose-escalation study in HLA-DR2+ MS subjects. Consecutive cohorts received RTL1000 doses of 2, 6, 20, 60, 200, and 100 mg, respectively. Subjects within each cohort randomly received a single intravenous infusion of RTL1000 or placebo at a 4 : 2 ratio. Safety monitoring included clinical, laboratory, and brain magnetic resonance imaging (MRI) evaluations. Results. Thirty-four subjects completed the protocol. All subjects tolerated the 2–60 mg doses of RTL1000. Doses ≥100 mg caused hypotension and diarrhea in 3 of 4 subjects, leading to discontinuation of further enrollment. Conclusions. The maximum tolerated dose of RTL1000 in MS subjects is 60 mg, comparable to effective RTL doses in EAE. RTL1000 is a novel approach for MS treatment that may induce immunoregulation without immunosuppression and promote neural repair.

1. Introduction

The pathogenesis of MS likely involves increased CD4+ T-cell responses directed against myelin antigens, including myelin oligodendrocyte glycoprotein (MOG) [1]. Myelin-reactive T-cells are present even in healthy controls but are activated and occur at higher frequencies in MS subjects [2], due possibly to escape from tolerance mechanisms. An elusive goal for
the treatment of MS is the development of therapies that can reestablish tolerance without causing immunosuppression.

Encephalitogenic CD4+ T-cells respond to specific myelin peptides complexed with major histocompatibility (MHC) class II molecules on antigen-presenting cells (APC). Ligation of the CD4+ T-cell receptor in combination with costimulatory molecules results in activation of autoreactive T-cells that migrate into the central nervous system (CNS) and trigger an inflammatory cascade, resulting in tissue injury and clinical disease. A variety of approaches can block antigen-specific T-cell activation, including intravenous exposure to high doses of free antigen [3], presentation of antigen by modified APCs [4], oral ingestion of antigen [5, 6], or injection of MHC/antigen complexes [7, 8].

Injection of soluble MHC/antigen complexes suppresses clinical and histological signs of experimental autoimmune encephalomyelitis (EAE) [9, 10]. This strategy utilizes an encephalitogenic myelin peptide bound by autologous MHC class II alleles, inducing anergy after T-cell engagement of the soluble MHC/antigen complex in the absence of costimulatory molecules [11]. This approach for treatment of MS became practical by our development of recombinant single chain, two domain MHC class II molecules linked covalently to autoantigenic peptides [12]. These recombinant T-cell receptor ligands (RTLs) proved highly effective for reversing established EAE in several different rodent models [13–16]. To develop an RTL potentially effective for MS, we combined the immunodominant MOG-35-55 peptide with the β1-α1 domains of HLA-DR2 [17], the highest genetic risk factor that occurs in ~60% of North American and Northern European MS patients [18, 19]. We further demonstrated that this RTL construct, designated as RTL1000, was highly effective at suppressing and treating MOG-35-55 peptide-induced EAE in DR2 transgenic mice [14, 20].

To determine the maximum tolerated dose of RTL1000 in subjects with MS, we performed a multicenter, Phase 1, placebo-controlled, single dose-escalation study. This study demonstrated that a dose of 60 mg of RTL1000 was well tolerated and importantly is comparable to single doses of RTL1000 that are highly therapeutic in DR2 transgenic mice with MOG-35-55-induced EAE.

2. Materials and Methods

2.1. Subjects. This study was conducted under an FDA approved IND (no. 100128) by Artielle ImmunoTherapeutics, Inc., Tigard, OR, approved by Institutional Review Boards from the six participating institutions (Oregon Health & Science University, Portland, OR; Swedish Neuroscience Institute, Seattle, WA; University of Kansas Medical Center, Kansas City, KS; University School of Medicine, Indiana University MS Center, Indianapolis, IN; Yale University, New Haven, CT; University of Maryland School of Medicine, Baltimore, MD) and registered at http://www.clinicaltrials.gov/ (NCT00411723). All subjects gave informed consent before entering the study. Qualified subjects met the following inclusion/exclusion criteria: definite diagnosis of MS by McDonald criteria [21]; confirmed diagnosis of RRMS or SPMS; age 18–65; Expanded Disability Status Scale (EDSS) of 0.0 to 6.5; no clinical exacerbations within the 8 weeks before administration of study drug; HLA-DR2 positive; not pregnant or breastfeeding and using an acceptable form of birth control; no exposure to any investigational agent or use of recombinant interferon beta, glatiramer acetate, or systemic corticosteroids in the past 4 weeks; no treatment with a monoclonal antibody, natalizumab, or systemic immunosuppressants, including azathioprine, mycophenolate mofetil, methotrexate, cladribine, cyclophosphamide, or mitoxantrone in the past 6 months; no total lymphoid irradiation or bone marrow transplant at any time.

2.2. Study Design. This was a multicenter, double-blind, placebo-controlled Phase 1 dose-escalating trial with six consecutive treatment cohorts. The study was designed to enroll six MS subjects per cohort using a ratio of 4:2 subjects randomly assigned to receive a single dose of RTL1000 or placebo, respectively. Subjects were admitted to an inpatient research unit, received the study drug by intravenous (IV) infusion over approximately 1 hour (Cohorts 1–4) or 2 hours (Cohorts 5 and 6). Subjects were observed during the infusion and for 24 hrs afterward. To further evaluate safety, subjects were evaluated weekly for 28 days and again on month 3 when they exited the study.

2.2.1. Endpoints. The primary endpoints of the study were safety and determination of the maximum tolerated dose (MTD) of a single IV infusion of RTL1000. The secondary endpoint was to evaluate pharmacokinetics (PK) of RTL1000 in a subset of subjects. Safety laboratory parameters included electrocardiogram (EKG), vital signs, blood chemistries, complete blood count, and antibodies to RTL1000, MOG-35-55 peptide, and HLA-DR2. Clinical safety parameters included medical and neurologic history and examination, EDSS, 25-foot timed walk, 9-hole peg test, gadolinium-enhanced brain MRI, and adverse events. Clinical assessments were performed by site investigators who were masked to the treatment assignment of subjects.

Adverse events and laboratory results were graded according to the common terminology criteria for adverse events, CTCAE v3.0. Subjects were closely monitored for allergic or infusion reactions during the administration of the product. An independent Data Safety Monitoring Board (DSMB), comprised of two neurologists and a statistician, reviewed blinded data at the completion of each cohort and gave permission to initiate enrollment in the next cohort if prespecified safety criteria were met.

2.2.2. Procedure Time Points. Subjects enrolled in the trial underwent neurological examination and MRI scan at baseline. On Day 0, just prior to infusion of RTL1000 or placebo, blood was drawn and plasma frozen for later evaluation of antibody titers and concentrations of RTL1000. Additional blood was drawn during and immediately after the infusion for PK evaluation of RTL1000 levels in plasma in subjects who agreed to participate in the PK substudy. After completion of the infusion, subjects underwent brain MRI
(Day 28), neurological examination (Day 28 and 3 months) and antibody levels (Day 28 and 3 months).

2.2.3. RTL1000 and Placebo. RTL1000 was supplied as a sterile liquid for IV infusion. Each 10 mL vial contained 10 mg RTL1000 at a concentration of 1 mg/mL in 20 mM Tris buffer at pH 8.5. The placebo consisted of Tris buffer solution only, which was visually indistinguishable from the solution with RTL1000. RTL1000 or placebo was infused over 1 hour for doses of ≤60 mg and 2 hours for doses of 100–200 mg. RTL1000 or placebo labeled in a blinded fashion with the subject randomization number was shipped for each subject.

2.2.4. Clinical and Safety Monitoring. Safety and tolerability were evaluated throughout the study by monitoring subject chemistry and hematology laboratory panels, EKGs, MRIs, neurologic and physical examinations, EDSS, 25-ft timed walk and 9-hole peg test.

2.2.5. MRI Procedures. Using a standardized procedure, brain MRIs were performed at baseline and Day 28. All study MRIs were screened at the individual study sites for incidental and nonstudy findings. MRIs were transferred electronically to a central reading center at the Portland VA Medical Center under the direction of Dr. Jack Simon. All MRI analyses were performed blinded to treatment allocation. The following assessments were made: total number of gadolinium enhancing lesions on the baseline and D28 scans and new and persistent gadolinium enhancing lesions and new and enlarging T2 hyperintensities on the D28 scan. The frequency of subjects with active scans (defined as those with ≥1 gadolinium enhancing lesions) in each cohort was also determined on the baseline and D28 MRI.

2.3. Assessment of Immunosuppression. Six subjects agreed to participate in an immunology substudy. For these subjects, peripheral blood mononuclear cells (PBMCs) were collected prior to infusion of drug or placebo and at 14 and 28 days after infusion and were stored in liquid nitrogen. Samples from each time point were cultured and analyzed as a group for reactivity to anti-CD3 mAb. Briefly, 250,000 PBMC were cultured in triplicate wells in RPMI 1640 with 1% pooled human serum in the presence of 1 μg anti-CD3 mAb or buffer control. Culture supernatants were collected after 48 h and sent to AssayGate, Inc. (Ijamsville, MD) for analysis of IL-1α, IL-6, IL-8, IL-10, IL-12(p40), IL-15, IL-17, IP-10, MCP-1, MIP-1α, MIP-β, and TNF-α.

2.4. Statistical Analyses

2.4.1. Study Conduct, Baseline Characteristics, and Safety. Descriptive statistics were used to summarize study conduct, baseline measures, and safety (including RRMS disease parameters).Adverse events were tabulated by dose cohort, system organ class, preferred term, according to frequency, severity, and investigator-determined relationship to study drug. Basic descriptive statistics for antibody O.D.s including mean ± SD were carried out for each sample collection time point, and P values were derived by applying Fisher’s exact test comparing the ratio of positive subjects receiving RTL1000 versus placebo at month 1 or month 3 versus baseline.

3. Results

3.1. Trial Profile. Between January, 2007, and November, 2008, after signing the informed consent, 108 MS subjects were initially assessed for eligibility and screened for HLA-DR2 (Figure 1). Of these, 50 did not meet inclusion criteria and 20 declined to participate. Of the remaining 38 subjects, 34 were randomized as described (Table 1). Four subjects who met entry criteria were not randomized as the study was stopped before they were randomized. All 34 treated subjects completed the protocol.

Upon the recommendation of the DSMB, Cohort 2 was repeated because one subject receiving 6 mg study drug developed chest pain. No adverse events were encountered with a second cohort (2A) receiving the same dose. Cohort 5, which received 200 mg, was stopped because two of the three subjects receiving study drug experienced significant infusion-related adverse events. With permission of the DSMB, Cohort 6 was initiated to receive an intermediate dose (100 mg), but treatment of this cohort was stopped after the first subject, who received study drug, experienced adverse events similar to those observed in Cohort 5.

3.2. Safety and Maximum Tolerated Dose

3.2.1. Adverse Events. No serious adverse events occurred during the study. RTL1000 infusions were well tolerated at doses of 60 mg or less. The overall incidence of adverse events was similar in subjects receiving RTL1000 versus placebo (87.0% RTL1000, 81.8% placebo). In subjects receiving RTL1000 at doses of 60 mg or less, adverse events did not differ between subjects receiving study drug and placebo aside from the occurrence of chest pain in one subject receiving 6 mg in Cohort 2. This subject experienced chest pain during the infusion that resolved and did not delay discharge; the event was assessed as treatment related by the site investigator; no cardiac or pulmonary etiology was found, despite extensive in-hospital workup. Chest pain did not occur in other subjects receiving RTL1000. Dose-limiting adverse events occurred in subjects receiving doses above 60 mg. One subject receiving 100 mg of RTL1000 had nausea, vomiting, diarrhea, headache, chills, and decreased blood pressure. Two of the three subjects who received 200 mg of RTL1000 experienced similar reactions, and these two subjects also experienced tachycardia, fever, and an increased neutrophil count. All events resolved within 24 hr and discharge from the inpatient research unit was not delayed. Based on these adverse events, the DSMB determined that the MTD had been achieved and was 60 mg. Two of 23 subjects (9%; mean annualized relapse rate of 0.35) receiving RTL1000 and one of 11 subjects (9%; mean annualized relapse rate of 0.36) receiving placebo had MS exacerbations.
Figure 1: Flow chart of subject enrollment and treatment. One hundred eight MS subjects were screened, with 67 testing positive for expression of HLA-DR2. Of these, 29 failed additional screening (did not meet EDSS requirement, were taking exclusionary drugs, or had a surgical procedure) or declined entry and 38 were enrolled in the trial.

during the follow-up period; the treating physicians believed that none of these events were treatment related and the DSMB agreed with this assessment.

Adverse events did not lead to subject withdrawal from the study. The most common adverse events in subjects receiving RTL1000 were headache (34.8%), vomiting (30.4%), and nausea (26.1%) and were assessed as treatment related in 26.1%, 26.1%, and 21.7% of subjects, respectively. Subjects receiving placebo had lower frequencies of these side effects: headache (27.3%), vomiting (0%), and nausea (9.1%). While headache, vomiting, and nausea at Grade 1 levels occurred across all dose groups, nausea and vomiting were more likely to be Grade 2 in the 100 and 200 mg dose groups.

3.2.2. RTL1000 Did Not Increase MS-Related Disease Activity. In this study RTL1000 treatment did not worsen MS as assessed by clinical safety endpoints (relapses, EDSS, timed walk, 9-hole peg test) and MRI. As shown in Table 2, the total number of gadolinium enhancing lesions and the number of new gadolinium enhancing and new and enlarging T2 hyperintensities did not increase significantly in any of the cohorts receiving RTL1000. As shown in Figure 2, the frequency of subjects with active MRI scans in the RTL1000 cohorts decreased in three cohorts and remained stable in one cohort following treatment. In the 20 mg cohort, none of the subjects had active scans at baseline and at D28 one subject had developed one gadolinium enhancing lesion. Frequency of subjects receiving placebo with active scans remained stable. Thus, there was no evidence of increased disease activity following RTL1000 administration.

3.2.3. RTL1000 Doses within the MTD Range in Subjects with MS Have Potent Therapeutic Activity at Comparable Doses in Mice with EAE. Based on body surface area measurements, the comparable dose of RTL1000 for treatment of EAE in mice is ~250X less than the dose used in humans [22]. Thus, 60 mg of RTL1000 in MS subjects is comparable to 240 μg in mice (Figure 3 inset). As shown in Figure 3, a single lower dose of 100 μg of the mouse MOG homologue of RTL1000 (equivalent to a 25 mg dose in humans) was sufficient to
**Table 1: Baseline demographics and clinical characteristics.**

| Characteristic                          | Placebo (N = 11) | 2 mg (N = 4)   | 6 mg (N = 7)   | 20 mg (N = 4)  | 60 mg (N = 4)  | 200 mg (N = 3) | 100 mg (N = 1) | Total (N = 34) |
|----------------------------------------|------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Female - N (%)                         | 8 (73)           | 4 (100)        | 5 (71)         | 3 (75)         | 4 (100)        | 2 (67)         | 0              | 26 (76)        |
| White - not hispanic or Latino - N     | 11               | 4              | 7              | 4              | 4              | 3              | 1              | 34             |
| Age mean (SD)                          | 52.0 (8.18)      | 54.3 (2.16)    | 53.0 (6.30)    | 58.5 (6.44)    | 55.9 (7.04)    | 50.3           | 38.8           | 53.2           |
| RRMS N (%)                             | 2 (18)           | 2 (50)         | 2 (29)         | 1 (25)         | 1 (25)         | 2 (67)         | 1 (100)        | 11 (32)        |
| SPMS N (%)                             | 9 (82)           | 2 (50)         | 5 (71)         | 3 (75)         | 3 (75)         | 1 (33)         | 0 (0)          | 23 (68)        |
| Number of relapses in the past year (SD)| 0.6 (0.81)      | 0.3 (0.50)     | 1.0 (1.15)     | 0.5 (0.58)     | 0.0 (0.00)     | 0.3 (0.47)     | 1              | 23 (68)        |
| Time since diagnosis years - mean (SD) | 14.5 (10.87)     | 13.2 (6.04)    | 13.5 (9.02)    | 12.1 (6.26)    | 19.6 (9.42)    | 7.3 (6.34)     | 2              | 9              |
| Time since last relapse months - mean (SD)| 58 (89.5)      | 42 (48.0)      | 48 (68.2)      | 69 (97.5)      | 77 (38.4)      | 32 (26.4)      | 0              | 5 (15)         |
| HLA DR2 homozygous N (%)               | 0                | 1 (25)         | 2 (29)         | 1 (25)         | 0              | 1 (33)         | 0              | 5 (15)         |
| EDSS score (min, max)                  | 5.41 (3.0, 7.0)  | 3.38 (2.0, 4.0) | 5.71 (3.0, 6.5) | 5.00 (4.0, 6.0) | 4.88 (3.0, 6.5) | 3.87 (2.5, 6.0) | 2.5            |
Table 2: Brain MRI outcomes in the placebo and RTL1000-treated subjects.

| Cohort (N) | Baseline—Gadolinium lesion Total count Mean (min, max) | Day 28—Gadolinium lesion Total count Mean (min, max) | Day 28—New Gadolinium lesion count Mean (min, max) | Day 28—New and Enlarging T2 lesion count Mean (min, max) |
|------------|-----------------------------------------------------------|------------------------------------------------------|--------------------------------------------------|--------------------------------------------------------|
| Placebo (11) | 1.6 (0, 9) | 1.4 (0, 8) | 0.6 (0, 2) | 0.5 (0, 3) |
| 2 mg dose (4) | 0.8 (0, 2) | 0.5 (0, 2) | 0.5 (0, 2) | 0.8 (0, 2) |
| 6 mg dose (7) | 0.9 (0, 4) | 0.4 (0, 2) | 0.0 (0, 0) | 0.1 (0, 1) |
| 20 mg dose (4) | 0.0 (0, 0) | 0.3 (0, 1) | 0.3 (0, 1) | 0.3 (0, 1) |
| 60 mg (4) | 0.3 (0, 1) | 0.3 (0, 1) | 0.0 (0, 0) | 0.0 (0, 0) |
| 100 mg (1) | 1.0 (1, 1) | 0.0 (0, 0) | 0.0 (0, 0) | 0.0 (0, 0) |
| 200 mg (3) | 0.0 (0, 0) | 0.0 (0, 0) | 0.0 (0, 0) | 0.0 (0, 0) |
produce sustained reversal of paralytic signs of MOG-35-55-induced EAE in DR2 transgenic mice over 28 days. These data demonstrate the potent clinical efficacy of RTL1000 homologue in EAE at a dose well within the comparable MTD range in MS subjects.

3.2.4. Treatment with RTL1000 Did Not Induce Immunosuppression. Six subjects were evaluated for immunosuppression by assessment of cytokines and chemokines in 48 h supernatants from anti-CD3 mAb-stimulated PBMC cultures prior to and at 14 d and 28 d after infusion of RTL1000 (three subjects receiving 200 mg drug and two receiving 60 mg drug) or placebo (1 subject). No significant reduction was observed in the levels of any of the 12 factors tested, including as examples, IL-6 and MIP-1α (Figure 4), suggesting that a single infusion of RTL1000 did not induce immunosuppression.

3.2.5. Treatment with RTL1000 Did Not Induce Significant Changes in Antibody Activity. ELISA evaluation of sera collected post- versus pre-infusion revealed that the number of MS subjects receiving any dose of RTL1000 who met the criteria for increased levels of IgG and/or IgM antibody to RTL1000 was not significantly different from the number of antibody positive MS subjects receiving placebo (8/20 versus 2/11, P = 0.262). Of these, 2 of 8 subjects receiving drug and 1 of 2 receiving placebo had increased antibody responses to DR2, and none had antibody responses to MOG-35-55 peptide. Moreover, the magnitude of IgG or IgM antibody reactivity after infusion versus baseline was not significantly different between the RTL1000 versus placebo-treated groups (Supplementary Figure 1 available online at doi:10.1155/2012/954739).

3.2.6. Pharmacokinetic Profile of RTL1000. PK was determined on plasma from five subjects that received RTL1000 (two received 6 mg; one, 100 mg and two, 200 mg). Subjects receiving 6 mg were infused over 60 minutes and subjects receiving 100 and 200 mg were infused over 120 minutes. Blood plasma samples were collected prior to, during, and after the infusion procedure and were evaluated for RTL1000 levels using sandwich ELISA. The concentration of RTL1000 in plasma is shown in Figure 5 for subjects receiving 6 mg of RTL1000 and for the subject receiving 100 mg. Individual linear regression parameters used to determine the RTL1000 half-lives could be derived in only five of the subjects receiving active drug. RTL1000 was not detected in subjects receiving placebo. Among the five patients receiving drug, the mean ± SD half-life was 4.86 ± 2.04 min with a range of 2.73 to 7.04 min. When the dose was increased from 20 to 60 to 200 mg in Cohorts 3, 4, and 5, the mean $C_{\text{max}}$ increased from 3.67 to 12.4 to 70.7 ng/mL, respectively. Total exposure (as assessed using $AUC_{\text{0-28d}}$) increased from 35 to 844 to 5090 hr*ng/mL, respectively. Thus, at these three dose levels, a trend of increasing exposure as assessed by $C_{\text{max}}$ and $AUC_{\text{0-28d}}$ with dose was observed. Clearance (CL) and volume of distribution could be assessed in only 3 patients (from Cohorts 4 to 6). In these patients, CL ranged from 3250 to 44800 mL/min and volume of distribution ranged from 30.8 to 202 liters. The very high clearance values are
4. Discussion

This is the first Phase 1 study of any recombinant T-cell receptor ligand in humans. We found that a single infusion of RTL1000 in HLA-DR2+ MS subjects was well tolerated at doses of 60 mg or less. Our study also found single infusion of RTL1000 to be safe as there was no indication of immunosuppression or liver enzyme abnormalities in the treated subjects. Subjects receiving RTL1000 did not develop significant antibody responses against RTL1000, DR2 or MOG peptide and there was no evidence of disease activation as detected clinically or by MRI. Importantly, an RTL1000 dose of 60 mg in MS subjects is equivalent to ~240 μg in mice and administration of a single 100 μg dose of a murine RTL1000 homologue was highly effective in treating EAE in DR2 transgenic mice. Thus the maximum tolerated dose of RTL1000 is in a therapeutic range based on EAE studies.

The homologues of RTL1000 designed to treat murine EAE have a remarkable ability to rapidly reverse clinical and histological signs of EAE without causing immunosuppression or toxicity. In a recent report [23], we reviewed preclinical data showing the ability of RTLs to inhibit both targeted cognate and bystander encephalitogenic Th1 and Th17 T-cell specificities in DR2 transgenic [14, 20, 24], C57BL/6 [16, 25], and SJL/J mice [15, 26]. Thus RTL treatment is effective in EAE models induced with three different myelin peptides and involving three different MHC Class II molecules. Importantly, RTLs block entry of inflammatory cells into the CNS [16] and promote remyelination and axonal regeneration in mice with chronic EAE [27, 28]. These studies provide compelling preclinical evidence that RTL1000 therapy in MS has the potential to regulate both MOG-35-55 peptide-specific and bystander T-cells of other specificities, inhibit entry of inflammatory cells into the CNS, and promote remyelination.

RTL1000 is an antigen specific therapy designed to modulate the pathogenic inflammatory response in MS without suppressing the immune system. Because it specifically
modulates the immune system, the long-term safety profile of RTL1000 is likely to be better than that of monoclonal antibodies, such as natalizumab, daclizumab and alemtuzumab, and small molecules, such as fingolimod and cladribine, that are immunosuppressive, cause profound lymphocytopenia or alter immunosurveillance within the CNS [29–31]. Antigen specific therapies have the potential to activate MS by stimulating pathogenic T cells as occurred with an altered peptide ligand for MBP-83-99 [32]. We did not observe disease activation in this Phase 1 trial and believe activation is unlikely, as the unique RTL1000 construct ensures that MOG-35-55 peptide-specific T-cells will interact with antigen in the absence of costimulatory molecules. Other antigen-specific therapies, such as oral myelin, intravenous MBP-82-98 peptide [33] and an MBP DNA vaccine [34], have been assessed in MS and were not effective. We believe that RTL1000 is more likely to prove effective because its unique design renders it more efficient at modulating pathogenic immune responses than free peptide or a DNA vaccine. Finally, unlike other antigen-specific therapies, our preclinical studies in EAE suggest that RTL1000 may promote remyelination. Thus RTL1000 represents a promising and novel therapy for MS.

The PK of RTL1000 is of interest. PK analysis of RTL1000 revealed a dose-dependent increase in exposure and a short half-life of ∼5 min only for subjects receiving drug. These data are remarkably similar to our preclinical studies in mice that demonstrated a similar half-life (∼10 min, data not shown). The rapid half-life and clearance values and the high nonphysiological volume of distribution suggest that RTL1000 binds to cellular components in blood or possibly to the vascular endothelium. In this regard, RTL binding to mouse antigen-presenting cells inhibited T-cell activation and transfer of EAE [35], and RTL1000 binding to human platelets reduced platelet aggregation and prolonged occlusive thrombus formation in blood [36]. Taken together, these findings suggest that the rapid compartmentalization of RTL1000 to circulating cells and platelets enables inhibitory activity, which may be important to its therapeutic mechanism of action.

The study’s limitations include a small sample size, inclusion of a mixture of MS populations, that is, subjects with relapsing remitting as well as secondary progressive subtypes, and relatively short followup. We also only administered a single infusion of RTL1000 and it is possible that disease activation, development of antibodies against RTL1000, DR2 or MOG peptide or other side effects might occur with multiple dosing of RTL1000. We are currently planning to test the safety and potential efficacy of multiple monthly infusions of RTL1000 in a Phase 2 trial.

In summary, our study shows that a single IV administration of RTL1000 is safe and well tolerated up to 60 mg, a dose that is comparable to a clinically effective RTL dose in DR2 mice with EAE. Based on the extensive preclinical testing of RTL in EAE, RTL1000 offers the potential for controlling inflammation without causing immunosuppression and may promote remyelination. Because of its rapid and sustained anti-inflammatory effects and based on the results obtained in the EAE experiments of RTL, a single dose of RTL1000 might be effective in treating relapses of MS. In addition, evaluation of the safety and potential efficacy of monthly infusions of RTL1000 as a long-term treatment for MS may also be warranted given its potent anti-inflammatory effects and apparent ability to promote repair in EAE.

Conflict of Interests

Dr. V. Yadav received research support from Artielle ImmunoTherapeutics for conducting this clinical trial, has received personal compensation for serving as a Subsection coeditor for Current Neurology and Neuroscience Reports, as a consultant from Biogen Idec and for serving on the Speakers Bureau for Novartis. She receives research support from McDougall Foundation and NMSS.

Dr. D. N. Bourdette has received funding for travel from Biogen Idec, has received honoraria from UC Davis, Sacramento, and LSU, New Orleans, and is on the Speakers Bureau of Biogen Idec, EMD Serono, and Teva Neuroscience. Dr. Bourdette was the chair of the Data Safety Monitoring Board for a clinical study.

Dr. J. Bowen received research support from Artielle ImmunoTherapeutics for conducting this clinical trial. He receives research support from Acorda Therapeutics, Biogen, Celgene, DiaGenix, Genzyme, BioMS, EMS Serono, Novartis, Sanofi-Aventis, and UCB Inc. He has received personal compensation as a consultant and a speaker for Acorda Therapeutics, Berlex, Biogen IDEC, Pfizer Serono, Novartis and Teva Neurosciences.

Dr. S. G. Lynch received research support from Artielle ImmunoTherapeutics for conducting this clinical trial. She is involved in multiple clinical trials with Novartis, Biogen, Bayer, Teva, Genzyme, Genentech, Accorda, Cephalon, and Eli Lilly Pharmaceuticals.

Dr. D. Mattson received research support from Artielle ImmunoTherapeutics for conducting this clinical trial. He is involved as an investigator for clinical drug trials funded by Biogen-Idec, Teva Neurosciences, Novartis, Bayer, EMD-Serono, Genzyme, Eli Lilly, Acorda Pharmaceuticals, ONO Pharmaceutical Corporation, and Actelion Corporation. He is on the Speakers Bureau for Biogen Idec, Bayer, Teva Neuroscience, EMD-Serono, Pfizer, and Acorda. He is a consultant for Eli Lilly, Biogen-Idec, EMD-Serono, Teva Neuroscience, and Novartis.

Dr. J. Preiningerova received consulting fees from Biogen Idec, Merck Serono, Teva and Bayer. Dr. J. Preiningerova received research support from Artielle ImmunoTherapeutics for conducting this clinical trial. She received financial support for research activities from Biogen Idec, Merck Serono, Teva and Acorda Pharmaceuticals.

Dr. C. T. Bever has no conflicts relevant to this publication/product.

Dr. J. Simon received research support from Artielle ImmunoTherapeutics for conducting this clinical trial. He has received research funding, speaking, and consultant fees from Biogen Idec. This potential conflict of interests has been reviewed and managed by the VAMC Conflict of Interest in Research Committee. He has also received honoraria as
consultant, speaker, DSMB, and/or research support from Genentech, Bristol-Myers Squibb, BioMS, Genzyme, and Protein Design Labs.

Mr. A. Goldstein received personal compensation and stock options from Artielle ImmunoTherapeutics as an employee.

Dr. G. G. Burrows is a consultant on an STTR project awarded to Artielle ImmunoTherapeutics, Inc. Dr. Burrows is an inventor of the RTL technology and has a significant financial interest in Artielle ImmunoTherapeutics, Inc., a company that may have a commercial interest in the results of this research and technology. This potential conflict of interest has been reviewed and managed by OHSU and the Integrity Program Oversight Council.

Dr. H. Offner received personal compensation from Artielle ImmunoTherapeutics, Inc. for consulting services. She is an inventor of the RTL technology and has a significant financial interest in Artielle ImmunoTherapeutics, Inc., a company that may have a commercial interest in the results of this research and technology. This potential conflict of interests has been reviewed and managed by the OHSU and VAMC Conflict of Interest in Research Committees.

Dr. A. J. Ferro received personal compensation and stock options from Artielle ImmunoTherapeutics as an employee.

Dr. A. A. Vandenbark received personal compensation from Artielle ImmunoTherapeutics, Inc. for consultation services. He is an inventor of the RTL technology and has a significant financial interest in Artielle ImmunoTherapeutics, Inc., a company that may have a commercial interest in the results of this research and technology. This potential conflict of interests has been reviewed and managed by the OHSU and VAMC Conflict of Interest in Research Committees.

Acknowledgments

This work was supported by the National Multiple Sclerosis Society (Grants nos. RG3794B, RG3794A, and RG3468A); NIH (Grants nos. NS47661, AI43960, NS41965, and NS46877), and Artielle ImmunoTherapeutics, Inc. This material is based upon work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development. The contents do not represent the views of the Department of Veterans Affairs or the United States Government. The authors wish to thank the members of the DSMB, Thomas R. Fleming, PhD (Chair), Jeffrey M. Cohen, MD, and John W. Rose, MD, Emmanuelle Waubant, MD, for providing an independent review of the adverse event in one MS subject in Cohort 2, Richard Stead, MD, and Dawn McGuire, MD, FAAN for serving as medical directors for the trial and Ms. Eva Niehaus for assistance in preparing the paper. The authors also wish to acknowledge the contributions of Shayne Andrew (preparing graphics), Prenn Ravey (antibody and PK assays), and Dr. Joe Hirman for statistical analyses for the trial.

References

[1] B. Bielekova, M. H. Sung, N. Kadom, R. Simon, H. McFarland, and R. Martin, “Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis,” Journal of Immunology, vol. 172, no. 6, pp. 3893–3904, 2004.
[2] N. Hellings, M. Bare, C. Verhoeven et al., "T-cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controls," Journal of Neuroscience Research, vol. 63, no. 3, pp. 290–302, 2001.
[3] A. Gaur, B. Wiers, A. Liu, J. Rothbard, and C. G. Fathman, "Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy," Science, vol. 258, no. 5087, pp. 1491–1494, 1992.
[4] M. K. Kennedy, L. J. Tan, M. C. Dal Canto, and S. D. Miller, “Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction,” Journal of Immunology, vol. 145, no. 1, pp. 117–126, 1990.
[5] P. V. Lehmann, T. Forsthuber, A. Miller, and E. E. Sercarz, “Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen,” Nature, vol. 358, no. 6382, pp. 155–157, 1992.
[6] C. C. Whitacre, I. E. Gienapp, C. G. Oroz, and D. M. Bitar, “Oral tolerance in experimental autoimmune encephalomyelitis: III. Evidence for clonal anergy,” Journal of Immunology, vol. 147, no. 7, pp. 2155–2163, 1991.
[7] S. D. Sharma, B. Nag, X. M. Su et al., “Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 24, pp. 11465–11469, 1991.
[8] H. Kozono, J. White, J. Clements, P. Marrack, and J. Kappler, “Production of soluble MHC class II proteins with covalently bound single peptides,” Nature, vol. 369, no. 6476, pp. 151–154, 1994.
[9] H. Appel, N. P. Seth, L. Gauthier, and K. W. Wucherpfennig, “Anergy induction by dimeric TCR ligands,” Journal of Immunology, vol. 166, no. 8, pp. 5279–5285, 2001.
[10] B. Nag, T. Kendrick, S. Arimilli, S. C. T. Yu, and S. Sirram, “Soluble MHC II—peptide complexes induce antigen-specific apoptosis in T cells,” Cellular Immunology, vol. 170, no. 1, pp. 25–33, 1996.
[11] M. K. Jenkins, P. S. Taylor, S. D. Norton, and K. B. Urda.hl, “CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells,” Journal of Immunology, vol. 147, no. 8, pp. 2461–2466, 1991.
[12] G. G. Burrows, J. W. Chang, H. P. Bächinger, D. N. Bourdette, H. Offner, and A. A. Vandenbark, “Design, engineering and production of functional single-chain T cell receptor ligands,” Protein Engineering, vol. 12, no. 9, pp. 771–778, 1999.
[13] H. Offner, S. Sinha, C. Wang, G. G. Burrows, and A. A. Vandenbark, “Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis,” Reviews in the Neurosciences, vol. 19, no. 4-5, pp. 327–339, 2008.
[14] A. A. Vandenbark, C. Rich, J. Mooney et al., “Recombinant TCR ligand induces tolerance to myelin oligodendrocyte glycoprotein 35–55 peptide and reverses clinical and histological signs of chronic experimental autoimmune encephalomyelitis in HLA-DR2 transgenic mice,” Journal of Immunology, vol. 171, no. 1, pp. 127–133, 2003.
[15] J. Huan, S. Subramanian, R. Jones et al., “Monomeric recombinant TCR ligand reduces relapse rate and severity of experimental autoimmune encephalomyelitis in SJL/J mice.
through cytokine switch,” Journal of Immunology, vol. 172, no. 7, pp. 4556–4566, 2004.

[16] S. Sinha, S. Subramanian, T. M. Proctor et al., “A promising therapeutic approach for multiple sclerosis: recombinant T-cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNS,” Journal of Neuroscience, vol. 27, no. 46, pp. 12531–12539, 2007.

[17] J. W. Chang, D. E. Mechling, H. F. Bächinger, and G. G. Burrows, “Design, engineering, and production of human recombinant T cell receptor ligands derived from human leukocyte antigen DR2,” Journal of Biological Chemistry, vol. 276, no. 26, pp. 24170–24176, 2001.

[18] S. Sawcer, M. Maranian, E. Setakis et al., “A whole genome screen for linkage disequilibrium in multiple sclerosis confirms disease associations with regions previously linked to susceptibility,” Brain, vol. 125, no. 6, pp. 1337–1347, 2002.

[19] G. C. Ebers, K. Kukay, D. E. Bulman et al., “A full genome search in multiple sclerosis,” Nature Genetics, vol. 13, no. 4, pp. 472–476, 1996.

[20] Y. K. Chou, N. Culbertson, C. Rich et al., “T-cell hybridoma specific for myelin oligodendrocyte glycoprotein-35–55 peptide produced from HLA-DRB1*1501-transgenic mice,” Journal of Neuroscience Research, vol. 77, no. 5, pp. 670–680, 2004.

[21] W. I. McDonald, A. Compston, G. Edan et al., “Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis,” Annals of Neurology, vol. 50, no. 1, pp. 121–127, 2001.

[22] S. Reagan-Shaw, M. Nihal, and N. Ahmad, “Dose translation from animal to human studies revisited,” The FASEB Journal, vol. 22, no. 3, pp. 659–661, 2008.

[23] H. Offner, S. Sinha, G. G. Burrows, A. J. Ferro, and A. A. Vandenbark, “RTL therapy for multiple sclerosis: a phase I clinical study,” Journal of Neuroimmunology, vol. 231, no. 1-2, pp. 7–14, 2011.

[24] J. M. Link, C. M. Rich, M. Korat, G. G. Burrows, H. Offner, and A. A. Vandenbark, “Monomeric DR2/MOG-35–55 recombinant TCR ligand treats relapses of experimental encephalomyelitis in DR2 transgenic mice,” Clinical Immunology, vol. 123, no. 1, pp. 95–104, 2007.

[25] S. Sinha, S. Subramanian, A. Emerson-Webber et al., “Recombinant TCR ligand reverses clinical signs and CNS damage of EAE induced by recombinant human MOG,” Journal of Neuroimmune Pharmacology, vol. 5, no. 2, pp. 231–239, 2010.

[26] S. Sinha, S. Subramanian, L. Miller et al., “Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single Recombinant T-cell receptor ligand,” Journal of Neuroscience, vol. 29, no. 12, pp. 3816–3823, 2009.

[27] H. Offner, S. Subramanian, C. Wang et al., “Treatment of passive experimental autoimmune encephalomyelitis in SJL mice with a recombinant TCR ligand induces IL-13 and prevents axonal injury,” Journal of Immunology, vol. 175, no. 6, pp. 4103–4111, 2005.

[28] C. Wang, B. G. Gold, L. J. Kaler et al., “Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE,” Journal of Neurochemistry, vol. 98, no. 6, pp. 1817–1827, 2006.

[29] O. Aktas, P. Küry, B. Kieseier, and H. P. Hartung, “Fingolimod is a potential novel therapy for multiple sclerosis,” Nature Reviews Neurology, vol. 6, no. 7, pp. 373–382, 2010.

[30] H. P. Hartung, O. Aktas, B. Kieseier, and G. Comi, “Development of oral cladribine for the treatment of multiple sclerosis,” Journal of Neurology, vol. 257, no. 2, pp. 163–170, 2010.